Continue for up to 18 h at the discretion of the physician. A lower-dose regimen for tirofiban is FDA approved and has been shown to be effective when used to treat UA/NSTEMI patients who are started on medical therapy and when there is a substantial delay to angiography/ PCI (eg, 48 h): LD of 50 mcg/mL administered at an initial rate of 0.4 mcg/kg per min for 30 min MD of a continuous infusion of 0.1 mcg/kg per min. Continue the infusion through angiography and for 12 to 24 h after angioplasty or atherectomy. P2Y12 Receptor Inhibitors Clopidogrel If 600 mg given orally, then no additional treatment A second LD of 300 mg may be given orally to supplement a prior LD of 300 mg (Class I, LOE: C) LD of 300 600 mg orally (Class I, LOE: A) MD of 75 mg orally per d (Class I, LOE: A) MD of 150 mg orally per d for initial 6 d may be considered (Class IIb, LOE: B) Optimum LD requires clinical consideration. Dose for patients 75 y of age has not been established. There is a recommended duration of therapy for all post-PCI patients receiving a BMS or DES. Caution should be exercised for use with a PPI. Period of withdrawal before surgery should be at least 5 d. (For full explanations, see footnote.) Prasugrel No data are available to guide decision making LD of 60 mg orally (Class I, LOE: B) MD of 10 mg orally per d (Class I, LOE: B) There are no data for treatment with prasugrel before PCI. MD of 5 mg orally per d in special circumstances. Special dosing for patients 60 kg or 75 y of age. There is a recommended duration of therapy for all post-PCI patients receiving a DES. 